Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Accumulated Expenses (2016 - 2025)

Avanos Medical (AVNS) has disclosed Accumulated Expenses for 13 consecutive years, with $91.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses changed 0.0% to $91.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.3 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $91.3 million for FY2025, 0.0% changed from the prior year.
  • Accumulated Expenses hit $91.3 million in Q4 2025 for Avanos Medical, up from $74.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $97.8 million in Q4 2022 to a low of $59.6 million in Q3 2021.
  • Historically, Accumulated Expenses has averaged $79.1 million across 5 years, with a median of $78.7 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: plummeted 32.2% in 2021 and later soared 43.61% in 2022.
  • Year by year, Accumulated Expenses stood at $68.1 million in 2021, then skyrocketed by 43.61% to $97.8 million in 2022, then decreased by 4.7% to $93.2 million in 2023, then decreased by 2.04% to $91.3 million in 2024, then changed by 0.0% to $91.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for AVNS at $91.3 million in Q4 2025, $74.8 million in Q3 2025, and $66.0 million in Q2 2025.